Vistagen Therapeutics (VTGN) to Release Quarterly Earnings on Tuesday

Vistagen Therapeutics (NASDAQ:VTGN) is expected to post its quarterly earnings results before the market opens on Tuesday, February 11th. Analysts expect Vistagen Therapeutics to post earnings of ($0.48) per share and revenue of $0.18 million for the quarter.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%. The business had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.34 million. During the same period in the prior year, the company posted ($0.66) earnings per share. On average, analysts expect Vistagen Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vistagen Therapeutics Stock Up 0.7 %

Shares of VTGN opened at $2.91 on Tuesday. The company’s 50 day moving average price is $2.78 and its 200 day moving average price is $3.04. Vistagen Therapeutics has a 52 week low of $2.22 and a 52 week high of $5.74.

About Vistagen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.